Announcements

Clinuvel's company releases, including archives.

Wednesday, 29 October 2014 09:26

Appendix 4C (Q1 2014-15)

Tuesday, 28 October 2014 15:13

Clinuvel to host investor teleconference

Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) will host an investor teleconference on Wednesday October 29 at the following times: Melbourne: 18:00Singapore: 15:00Zurich: 08:00New York: 03:00 Investors can access the call by calling the numbers below and entering the conference PIN 758468# Country Number Australia +61 2 8417 2751 Austria +43 7 2088 1060 China +86 400 716 0165 France +33 9 7518 0198 Germany +49 89 2109 4210 Hong Kong +852 5808 0301 Italy                 +39 06 9926 8246 Netherlands +31 85 888 0207 Singapore                 +65 3158 5152 Switzerland +41 22 533 0940 UK +44 20…
Monday, 27 October 2014 15:36

Notice of Meeting/Proxy Form

Australia’s Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) has announced that its drug SCENESSE® (afamelanotide 16mg) has received its first approval from the European Medicines Agency (EMA) to treat a disease caused by exposure to sunlight. The EMA’s Committee for Medicinal Products for Human Use (CHMP) voted in favour of marketing authorisation for SCENESSE® under exceptional circumstances for the rare genetic disorder erythropoietic protoporphyria (EPP). SCENESSE® is the first treatment ever to have been developed for EPP, a debilitating disorder which is clinically regarded as extreme intolerance to light and UV (phototoxicity). These patients suffer from intolerable pain,…
European Medicines Agency CHMP approves novel drug for erythropoietic protoporphyria patients under exceptional circumstances (ART 14 (8) OF REGULATION (EC) NO 726/2004) EXECUTIVE SUMMARY SCENESSE® attains an historic breakthrough EMA approval for adult EPP patients extremely intolerant of light and UV Marketing authorisation in 31 European States Australian listed Clinuvel (ASX: CUV) has taken SCENESSE® from discovery to commercialisation SCENESSE® as the first drug for which patients’ and physicians’ clinical experiences were integrated EMA’s formal decision process Investor telephone conference-call Wednesday 29 October: 1800 Melbourne = 0900 Zurich = 0300 New York = 1500 Singapore. Details will be released to…
- Media release - The first new pharmaceutical drug invented and developed for an untreated disorder by any Australian company has received regulatory approval from the European Medicines Agency (EMA). SCENESSE® (afamelanotide 16mg) treats the debilitating genetic disorder porphyria (EPP), or absolute intolerance to sunlight. The fear of lifelong burns requires EPP patients to lead an indoor, isolated existence avoiding any form of light. SCENESSE® is the first treatment ever to have been developed for EPP. EPP is characterised by an extreme risk of severe burns (phototoxicity) of the skin resulting in intolerable pain, swelling, scarring and a state of…
Thursday, 23 October 2014 10:00

Trading Halt - October 24

Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) wishes to advise in accordance with the terms and conditions of issue that the following unquoted conditional performance rights have lapsed and forfeited. Class Number Exercise price CUVAK Conditional Performance Rights subject to various performance milestones 50,000 $Nil Consequently, there are now 1,341,482 unlisted conditional performance rights on issue. - End - Investor relations contacts: Australia: Clinuvel Pharmaceuticals Limited, T: +61 3 9660 4900Europe: Clinuvel AG, T: +41 41 763 54 30Email About Clinuvel Pharmaceuticals LimitedClinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) is a global biopharmaceutical company focused on…
In accordance with ASX listing rules 3.13.1 and 14.3, Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced it will hold its 2014 Annual General Meeting of shareholders on Friday November 28, 2014 at 10.00am AEST at Karstens Conference Centres, Level 8, Room 803, 123 Queen Street, Melbourne, Victoria, Australia 3000 A formal Notice of Meeting and the Company’s Annual Report will be lodged with the ASX no later than October 27, 2014. – End – Investor relations contacts: Australia: Clinuvel Pharmaceuticals Limited, T: +61 3 9660 4900Europe: Clinuvel AG, T: +41 41 763 54 30Email About Clinuvel…
Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that data from the use of its drug SCENESSE® (afamelanotide 16mg) in clinical trials and special access schemes are being presented at the European Academy for Dermatology and Venereology (EADV) meeting in Amsterdam, held from 8-12 October. Results from the Phase II US study in vitiligo (CUV102) and clinical experiences of treating erythropoietic protoporphyria (EPP) patients during seven years in Switzerland and Italy are being discussed among specialists and dermatologists at the ‘MSH Society Meeting’ on October 8. This is the sixth consecutive year that clinical data from physicians…
Page 1 of 36

Share Price

Buy : 3.52

Sell : 3.7

First : 3.52

Last : 3.6

High : 3.75

Low : 3.52

ASX: CUV 20 mins delay.

Volume : 56,820 Trades: 225

Last Traded : 30-Oct-2014 16:10:29

Popular Articles

Investor Spotlight

Clinuvel Stock Ticker

Clinuvel Spotlight

Company History

The technology behind Clinuvel’s lead drug, SCENESSE® (afamelanotide 16mg), has been in research and development since the 1980s when a small team of scientists set out to investigate methods of preventing skin cancer in humans. Clinuvel licensed this technology and has spent over A$20million optimising the chemistry of afamelanotide (the active ingredient in SCENESSE...

Investors' Blog Posts

In 2010, Clinuvel announced that it would commence a clinical trial of a new drug for vitiligo. In late 2012 the first treatment results...

Clinuvel Non-Executive Director Brenda Shanahan has been honoured at The Australian Financial Review and Westpac Group Woman of Influence...

Since we publicly announced our vitiligo program in 2010, the entire Clinuvel team has aimed to gain a better understand this disease, its...

Related Webcasts

What can vitiligo patients do? - Lee Thomas and Dr ...

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

The future of vitiligo treatment - Lee Thomas and D...

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Vitiligo trials of SCENESSE® - Lee Thomas and Dr Ph...

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Quick Links